NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors

• Nicolas Duployez,
• Guillaume Grzych,
• Benoît Ducourneau,
• Martin Alarcon Fuentes,
• Nathalie Grardel,
• Thomas Boyer,
• Wadih Abou Chahla,
• Bénédicte Bruno,
• Brigitte Nelken,
• Emmanuelle Clappier,
• Claude Preudhomme

Affiliations

Nicolas Duployez

CHU Lille, Biology and Pathology Center, Laboratory of Hematology, Lille, France;INSERM UMR-S 1172, Cancer Research Institute, Lille, France

Guillaume Grzych

CHU Lille, Biology and Pathology Center, Laboratory of Hematology, Lille, France

Benoît Ducourneau

CHU Lille, Biology and Pathology Center, Laboratory of Hematology, Lille, France

Martin Alarcon Fuentes

CHU Lille, Jeanne de Flandre Hospital, Pediatric Hematology Department, Lille, France

Nathalie Grardel

CHU Lille, Biology and Pathology Center, Laboratory of Hematology, Lille, France

Thomas Boyer

CHU Lille, Biology and Pathology Center, Laboratory of Hematology, Lille, France;INSERM UMR-S 1172, Cancer Research Institute, Lille, France

Wadih Abou Chahla

CHU Lille, Jeanne de Flandre Hospital, Pediatric Hematology Department, Lille, France

Bénédicte Bruno

CHU Lille, Jeanne de Flandre Hospital, Pediatric Hematology Department, Lille, France

Brigitte Nelken

CHU Lille, Jeanne de Flandre Hospital, Pediatric Hematology Department, Lille, France

Emmanuelle Clappier

Assistance Publique-Hôpitaux de Paris, Saint Louis Hospital, Laboratory of Hematology, Paris, France

Claude Preudhomme

CHU Lille, Biology and Pathology Center, Laboratory of Hematology, Lille, France;INSERM UMR-S 1172, Cancer Research Institute, Lille, France